ARCHIVES

Nancy Brinker Resigns As CEO of Komen

This article is from The Cancer Letter archive.

Vol. 38 No. 32 | August 10, 2012

Download PDF Visit The Full Archive

Related Articles

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

April 13, 2007

Sexual Function Affected By Stem Cell Transplant

September 28, 2007

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

February 15, 2002

Evaluation Finds OIG Provides PIs With Flexibility

June 14, 1991

Cancer Program Progress Detailed

March 5, 1976